We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA, Industry Continue Talks on Biosimilar User Fees, Including Labeling Updates and Data and Tech Modernization
FDA, Industry Continue Talks on Biosimilar User Fees, Including Labeling Updates and Data and Tech Modernization
FDA and industry are going back to the drawing board on proposals for safety labeling updates, according to the latest GDUFA III meetings, which also included discussions on supplement reviews and continued talks on proposals for data and technology modernization, among other topics.